CN103920134A - Sustained release tablet for treating child vertigo and preparation method thereof - Google Patents
Sustained release tablet for treating child vertigo and preparation method thereof Download PDFInfo
- Publication number
- CN103920134A CN103920134A CN201410191470.0A CN201410191470A CN103920134A CN 103920134 A CN103920134 A CN 103920134A CN 201410191470 A CN201410191470 A CN 201410191470A CN 103920134 A CN103920134 A CN 103920134A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- dizzy
- radix
- child
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a sustained release tablet for treating child vertigo and a preparation method thereof. The sustained release tablet comprises the following composition, by weight part ratio, 240 parts to 360 parts of traditional Chinese medicine extracts, 70 parts to 90 parts of hydroxypropyl methylcellulose, 3 parts to 8 parts of release rate modifiers, 2 parts to 5 parts of adhesive of appropriate amount, and 15 parts to 25 parts of fillers, wherein each part of the traditional Chinese medicine extracts is prepared by 5 parts to 8 parts of traditional Chinese medicine codonopsis pilosula, 5 parts to 8 parts of atractylodes, 5 parts to 8 parts of dried gingers, 8 parts to 12 parts of cassia twigs, , 8 parts to 12 parts of rhizoma pinellinae praeparata, 8 parts to 12 parts of fructus trichosanthis, 8 parts to 12 parts of allium macrostemon Bunge, 8 parts to 12 parts of ophiopogon japonicus, 16 parts to 24 parts of lindera aggregate, 16 parts to 24 parts of radix glycyrrhizae preparata and 16 parts to 24 parts of poria cocos. In clinical observation, it is proved that the sustained release tablet for treating the child vertigo has good curative effects, and overcomes the defects that dosage of a conventional tablet is large, the times of taking medicine is many, patients dependence to the medicine is strong and the like.
Description
Technical field
The invention belongs to Chinese drug preparation field, be specifically related to dizzy slow releasing tablet of a kind of child for the treatment of and preparation method thereof
Background technology
Feature when onset of vertigo is usually can feel dizzy dizzy, even feels sick, vomits, emits the symptom of the vegetative dystonies such as cold sweat.According to statistics, vertigo accounts for 5% of outpatients in internal medicine clinics, accounts for 15% of hals,Nasen und Ohrenheilkunde outpatient service.Treatment vertigo method is varied at present, as operative treatment, western medicine: transfusion, oral flunarizine, betahistine, SHUXUENING etc., operative treatment is painful large, expense is high, though western medicine has been obtained certain curative effect, but just respite symptom, still outbreak repeatedly of patient afterwards, fundamentally do not remove patient's slight illness, and side effect is large, although what treatment by Chinese herbs was dizzy also has, but major part is ordinary preparation, slow curative effect, dosage is large, patient's submissiveness such as looks at the problem, therefore improvement and bring new ideas is imperative.
Child is dizzy is the moving property of one or positional illusion planotopokinesia being produced because of body, dizzy true vertigo and the nonsystemic vertigo of being divided into.True vertigo is caused have obvious foreign object or self sense of rotation by eye, proprioceptive sensation or vestibular system disease.Nonsystemic vertigo is many to be caused by whole body systemic disease, as cardiovascular disease, cerebrovascular disease, anemia, uremia, drug intoxication, endocrinopathy and neurosis etc. nearly all have weight dizzy symptom not etc., patient feels " fluttering is swung ", does not clearly rotate sense.And at present a lot of children exist this problem as long as because diet is unbalanced, quantity of motion is inadequate, especially suffers from the infant of obesity, and nutritional iron deficiency anemia can occur, and causes dizziness, the symptom such as weak.For safety, Chinese medicine draft therapy is proposed now.
Summary of the invention
The object of the present invention is to provide the dizzy slow releasing tablet of a kind of child for the treatment of.
Another object of the present invention is to provide a kind of child for the treatment of preparation method of dizzy slow releasing tablet.
Particularly, the present invention has following scheme to realize:
A kind of dizzy slow releasing tablet of child for the treatment of of the present invention, by weight, is made up of Chinese medicine extract 240-360 part, hypromellose 70-90 part, rate of release regulator 3-8 part, the appropriate 2-5 part of binding agent, filler 15-25 part.
Described Chinese medicine extract is by Chinese medicine Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, the each 5-8 part of Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis and Radix Ophiopogonis each 8-12 part, the each 16-24 part of the Radix Linderae, Radix Glycyrrhizae Preparata and Poria is made.Preferably, described Chinese medicine extract is by each 7 parts of Chinese medicine Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Zingiberis, and each 10 parts of Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis and Radix Ophiopogonis, each 20 parts of the Radix Linderae, Radix Glycyrrhizae Preparata and Poria are made.
Described Chinese medicine extract preparation method is:
1), take by weight percentage Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis, Radix Ophiopogonis, the Radix Linderae, Radix Glycyrrhizae Preparata and Poria;
2), to described Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis, in Radix Ophiopogonis, add and be equivalent to the ethanol water that quality of medicinal material 2-8 volumetric concentration is doubly 30%-70%, reflux, extract, 1-3 hour, filter, relative density is 1.05～1.30 by filtrate recycling ethanol and while being concentrated into 80 DEG C, let cool, with organic solvent extraction, extract reclaims organic solvent and concentrates to obtain extractum 1;
3), the described Radix Linderae, Radix Glycyrrhizae Preparata and Poria are added and be equivalent to the ethanol water that quality of medicinal material 2-8 volumetric concentration is doubly 30%-70%, reflux, extract, 1-3 hour, filter, by filtrate recycling ethanol and the concentrated solution that relative density is 1.05～1.30 while being concentrated into 80 DEG C, regulate pH value to be adjusted to 7-8, with organic solvent extraction, extract reclaims organic solvent and concentrates to obtain extractum 2;
4), extractum 1 and extractum 2 drying and crushing are mixed to get to Chinese medicine extract.
Described organic solvent is n-butyl alcohol, ethyl acetate, butanone, chloroform or petroleum ether.
The preparation method of described slow releasing tablet is: get by weight ratio above-mentioned Chinese medicine extract, filler, hypromellose and rate of release regulator, cross 60 mesh sieves and mix, add binding agent soft material processed in right amount, crossing 20 mesh sieves granulates, 40-50 DEG C dry, and dry granule is crossed 20 mesh sieve granulate, tabletting and get final product.Described hypromellose is selected from HPMC K4M, hypromellose K15M or hypromellose K100M.
Described rate of release regulator is selected from carboxymethyl starch sodium or polyvinylpolypyrrolidone.
It is the ethyl cellulose alcoholic solution that 3% polyvidone alcoholic solution or mass concentration are 3% that described binding agent is selected from mass concentration.
Described filler is microcrystalline Cellulose, calcium sulfate, lactose, polyvidone or amylum pregelatinisatum.
The present invention's medical material used, through scientific and reasonable compatibility, supports to each other mutually, the merit of playing altogether blood circulation promoting and blood stasis dispelling, suppressing the hyperactive liver, YANG hyperactivity suppressing, endogenous wind stopping relieving convulsion, liver and kidney tonifying, stomach function regulating preventing or arresting vomiting, is effective to treat vertigo, and through clinical practice, obtained satisfied effect, its interrelated data is as follows:
Between 2009-2013, utilize medicine of the present invention to treat altogether 105 routine patients, wherein male 60 examples, female's 45 examples, minimum 7 years old of age, maximum 15 years old, minimum 3 months of the course of disease is the longest 3 years.Clinical manifestation is to be outbreak paroxysm, peripheral vertigo, has normal interval time; One pick up the ears deaf, tinnitus often points out nervus cochleae to be involved, and patient occurs that symptom is the reliable markers of damaged peripheral nerves evil.Have 2-10s incubation period, the course of disease is short, permanent vertigo or disequilibrium companion's irregular nystagmus and gait disorder; Headache, diplopia, speech late slow, limb motion is inharmonious or one-sided paresis etc.; Tinnitus, feel sick, the symptom such as vomiting.
Therapeutic scheme, 3 treatment groups, every group of 25 people, take respectively the slow releasing tablet that embodiment of the present invention 1-3 makes, and sooner or later once, within 15 days, are a course for the treatment of, matched group, 30 people, conventional oral cinnarizine, three times on the one, each 2 15 days is a course for the treatment of.
The standard of efficacy evaluation: cure: dizzy symptom disappear completely (do not follow up a case by regular visits to and do not recur again after 6 months); Effective: transference cure is interrupted outbreak, accompanies slight sense of rotation, can adhere to study, but life is affected; Invalid: dizzy outbreak repeatedly, companion's nausea and vomiting symptom.
| Group | Number | Cure | Effectively | Invalid | Effective percentage % |
| Treatment group 1 | 25 | 15 | 7 | 3 | 88 |
| Treatment group 2 | 25 | 16 | 5 | 4 | 84 |
| Treatment group 3 | 25 | 17 | 6 | 2 | 92 |
| Matched group | 30 | 18 | 3 | 9 | 70 |
There were significant differences for treatment group and matched group clinical efficacy (P < 0.05), shows that successful is better than matched group.
Typical body case is as follows:
High certain, man, 13 years old, people from Zhengzhou City, fat 70 kilograms, he takes on arm numbness over 3 years, accompany by dizzy, heavy when light when the state of an illness, fail radical cure through western medicines in treatment.What suffer from after diagnosing is cervical vertigo, fully recover after taking 2 courses for the treatment of of Chinese medicine sustained release tablets of the present invention, and recurrence that so far there are no.
Lee, man, 14 years old, people from Chengdu, Sichuan, showed effect over 2 years dizzy, dizzy repeatedly, aggravation recently, outbreak is frequent, can not join into sports, and rises dizzy.After diagnosing suffer from be due to vertebra base tremulous pulse blood supply insufficiency cause dizzy, inner ear labyrinth artery origin is in posterior inferior cerebellar artery, it is the branch of vertebra basilar artery, vertebro-basilar artery insufficiency can affect lost blood supply and occur dizzy, after taking 3 courses for the treatment of of Chinese medicine sustained release tablets of the present invention, fully recover, within 1 year, do not recur again.
Detailed description of the invention
Embodiment 1
Raw material: Chinese medicine extract 2.4kg, HPMC K4M 0.9kg, polyvinylpolypyrrolidone 0.08kg, the ethyl cellulose alcoholic solution 0.02kg that mass concentration is 3%, microcrystalline Cellulose 0.25kg.
Preparation method:
1), take Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, the each 5kg of Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis and Radix Ophiopogonis each 8kg, the each 24kg of the Radix Linderae, Radix Glycyrrhizae Preparata and Poria;
2), to described Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis, in Radix Ophiopogonis, add and be equivalent to the ethanol water that the volumetric concentration of 2 times of quality of medicinal materials is 30%, reflux, extract, 1 hour, filter, relative density is 1.05 by filtrate recycling ethanol and while being concentrated into 80 DEG C, let cool, with n-butanol extraction, extract reclaims and concentrates and to obtain extractum 1;
3), the described Radix Linderae, Radix Glycyrrhizae Preparata and Poria are added and be equivalent to the ethanol water that the volumetric concentration of 2 times of quality of medicinal materials is 30%, reflux, extract, 1 hour, filter, by filtrate recycling ethanol and the concentrated solution that relative density is 1.05 while being concentrated into 80 DEG C, regulate pH value to be adjusted to 8, with there being n-butanol extraction, extract reclaims solvent and concentrates to obtain extractum 2;
4), extractum 1 and extractum 2 drying and crushing are mixed to get to Chinese medicine extract;
5), above-mentioned Chinese medicine extract, filler, hypromellose and rate of release regulator crossed to 60 mesh sieves mix, add binding agent soft material processed in right amount, cross 20 mesh sieves and granulate, 40 DEG C are dry, dry granule is crossed 20 mesh sieve granulate, tabletting and get final product every 0.5g.
Usage and dosage: one day twice, each a slice
Embodiment 2
Raw material: polyvidone alcoholic solution 0.02kg, filler lactose 0.15kg that Chinese medicine extract 3.6kg, hypromellose K15M0.7kg, rate of release regulator carboxymethyl starch sodium 0.03kg, the appropriate mass concentration of binding agent are 3%.
Preparation method:
1), Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, the each 8kg of Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis and Radix Ophiopogonis each 12kg, the each 16kg of the Radix Linderae, Radix Glycyrrhizae Preparata and Poria;
2), to described Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis, in Radix Ophiopogonis, add and be equivalent to the ethanol water that the volumetric concentration of 8 times of quality of medicinal materials is 70%, reflux, extract, 3 hours, filter, relative density is 1.30 by filtrate recycling ethanol and while being concentrated into 80 DEG C, let cool, with petroleum ether extraction, extract reclaims organic solvent and concentrates to obtain extractum 1;
3), the described Radix Linderae, Radix Glycyrrhizae Preparata and Poria are added and be equivalent to the ethanol water that the volumetric concentration of 8 times of Rhizoma Corydalis quality is 70%, reflux, extract, 3 hours, filter, by filtrate recycling ethanol and the concentrated solution that relative density is 1.30 while being concentrated into 80 DEG C, regulate pH value to be adjusted to 7, with petroleum ether extraction, extract reclaims organic solvent and concentrates to obtain extractum 2;
4), extractum 1 and extractum 2 drying and crushing are mixed to get to Chinese medicine extract;
5), above-mentioned Chinese medicine extract, filler, hypromellose and rate of release regulator crossed to 60 mesh sieves mix, add binding agent soft material processed in right amount, cross 20 mesh sieves and granulate, 45 DEG C are dry, dry granule is crossed 20 mesh sieve granulate, tabletting and get final product every 0.5g.
Usage and dosage: one day twice, each a slice.
Described slow releasing tablet can increase one deck coatings for the ease of taking: described coatings is slow release layer, comprises filmogen, porogen, plasticizer, antiplastering aid and solvent; Described filmogen is cellulose acetate, is ethyl cellulose; Its consumption is coating solution gross weight: 0.02%～5%; Described porogen is sodium lauryl sulphate, Macrogol 4000, hypromellose, cross-linking polyethylene pyrrolidone, and porogen consumption is 0.02%～8% of coating solution gross weight; Described antiplastering aid is Pulvis Talci, is magnesium stearate; Consumption is 0.05%～15% of coating solution gross weight; Described plasticizer is glycerol, Oleum Arachidis hypogaeae semen, diethyl phthalate, Polyethylene Glycol; Plasticizer consumption is the 0.02%-5% of coating solution gross weight; Described solvent is ethanol, methanol; Consumption is 70%～98% of coating solution gross weight.
Embodiment 3
Raw material: ethyl cellulose alcoholic solution 0.04kg, filler amylum pregelatinisatum 0.2kg that Chinese medicine extract 3.0kg, hypromellose hypromellose K100M0.8kg, rate of release regulator polyvinylpolypyrrolidone 0.06kg, binding agent mass concentration are 3%.
Preparation method:
1), Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, the each 6kg of Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis and Radix Ophiopogonis each 10kg, the each 20kg of the Radix Linderae, Radix Glycyrrhizae Preparata and Poria;
2), to described Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis, in Radix Ophiopogonis, add and be equivalent to the ethanol water that the volumetric concentration of 5 times of quality of medicinal materials is 50%, reflux, extract, 2 hours, filter, relative density is 1.20 by filtrate recycling ethanol and while being concentrated into 80 DEG C, let cool, with butanone extraction, extract reclaims organic solvent and concentrates to obtain extractum 1;
3), the described Radix Linderae, Radix Glycyrrhizae Preparata and Poria are added and be equivalent to the ethanol water that the volumetric concentration of 5 times of Rhizoma Corydalis quality is 50%, reflux, extract, 2 hours, filter, by filtrate recycling ethanol and the concentrated solution that relative density is 1.20 while being concentrated into 80 DEG C, regulate pH value to be adjusted to 7, with butanone extraction, extract reclaims organic solvent and concentrates to obtain extractum 2;
4), extractum 1 and extractum 2 drying and crushing are mixed to get to Chinese medicine extract;
5), above-mentioned Chinese medicine extract, filler, hypromellose and rate of release regulator crossed to 60 mesh sieves mix, add binding agent soft material processed in right amount, cross 20 mesh sieves and granulate, 45 DEG C are dry, dry granule is crossed 20 mesh sieve granulate, tabletting and get final product every 0.5g.
Usage and dosage: one day twice, each a slice
Described slow releasing tablet can increase one deck coatings for the ease of taking: described coatings is slow release layer, comprises filmogen, porogen, plasticizer, antiplastering aid and solvent; Described filmogen is cellulose acetate, is ethyl cellulose; Its consumption is coating solution gross weight: 0.02%～5%; Described porogen is sodium lauryl sulphate, Macrogol 4000, hypromellose, cross-linking polyethylene pyrrolidone, and porogen consumption is 0.02%～8% of coating solution gross weight; Described antiplastering aid is Pulvis Talci, is magnesium stearate; Consumption is 0.05%～15% of coating solution gross weight; Described plasticizer is glycerol, Oleum Arachidis hypogaeae semen, diethyl phthalate, Polyethylene Glycol one wherein; Plasticizer consumption is the 0.02%-5% of coating solution gross weight; Described solvent is one of ethanol, methanol; Consumption is 70%～98% of coating solution gross weight.
Finally it should be noted that: above embodiment only, in order to technical scheme of the present invention to be described, is not intended to limit; Although the present invention is had been described in detail with reference to previous embodiment, those of ordinary skill in the art is to be understood that: its technical scheme that still can record previous embodiment is modified, or part technical characterictic is wherein equal to replacement; And these amendments or replacement do not make the essence of appropriate technical solution depart from the spirit and scope of embodiment of the present invention technical scheme.
Claims (10)
1. treat the dizzy slow releasing tablet of child, it is characterized in that: by weight, formed by Chinese medicine extract 240-360 part, hypromellose 70-90 part, rate of release regulator 3-8 part, the appropriate 2-5 part of binding agent, filler 15-25 part.
2. the dizzy slow releasing tablet for the treatment of child as described in right 1, it is characterized in that, by weight, described Chinese medicine extract is by Chinese medicine Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, the each 5-8 part of Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis and Radix Ophiopogonis each 8-12 part, the each 16-24 part of the Radix Linderae, Radix Glycyrrhizae Preparata and Poria is made.
3. the dizzy slow releasing tablet for the treatment of child as claimed in claim 2, it is characterized in that, by weight, described Chinese medicine extract is by each 7 parts of Chinese medicine Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Zingiberis, each 10 parts of Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis and Radix Ophiopogonis, each 20 parts of the Radix Linderae, Radix Glycyrrhizae Preparata and Poria are made.
4. the dizzy slow releasing tablet for the treatment of child according to claim 1, is characterized in that, described Chinese medicine extract preparation method is:
1), take by weight percentage Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis, Radix Ophiopogonis, the Radix Linderae, Radix Glycyrrhizae Preparata and Poria;
2), to described Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Zingiberis, Ramulus Cinnamomi, Rhizoma Pinelliae Preparatum, Fructus Trichosanthis, Bulbus Allii Macrostemonis, in Radix Ophiopogonis, add and be equivalent to the ethanol water that quality of medicinal material 2-8 volumetric concentration is doubly 30%-70%, reflux, extract, 1-3 hour, filter, relative density is 1.05～1.30 by filtrate recycling ethanol and while being concentrated into 80 DEG C, let cool, with organic solvent extraction, extract reclaims organic solvent and concentrates to obtain extractum 1;
3), the described Radix Linderae, Radix Glycyrrhizae Preparata and Poria are added and be equivalent to the ethanol water that quality of medicinal material 2-8 volumetric concentration is doubly 30%-70%, reflux, extract, 1-3 hour, filter, by filtrate recycling ethanol and the concentrated solution that relative density is 1.05～1.30 while being concentrated into 80 DEG C, regulate pH value to be adjusted to 7-8, with organic solvent extraction, extract reclaims organic solvent and concentrates to obtain extractum 2;
4), extractum 1 and extractum 2 drying and crushing are mixed to get to Chinese medicine extract.
5. according to a kind of dizzy slow releasing tablet of child for the treatment of claimed in claim 4, it is characterized in that described organic solvent is n-butyl alcohol, ethyl acetate, butanone, chloroform or petroleum ether.
6. according to the arbitrary described dizzy slow releasing tablet for the treatment of of claim 1-5, it is characterized in that, the preparation method of described slow releasing tablet is: get by weight ratio described Chinese medicine extract, filler, hypromellose and rate of release regulator, crossing 60 mesh sieves mixes, add binding agent soft material processed in right amount, cross 20 mesh sieves and granulate, 40-50 DEG C dry, dry granule is crossed 20 mesh sieve granulate, tabletting and get final product.
7. the dizzy slow releasing tablet for the treatment of according to claim 1, is characterized in that described hypromellose is selected from HPMC K4M, hypromellose K15M or hypromellose K100M.
8. a kind of dizzy slow releasing tablet of child for the treatment of according to claim 1, is characterized in that described rate of release regulator is selected from carboxymethyl starch sodium or polyvinylpolypyrrolidone.
9. a kind of dizzy slow releasing tablet of child for the treatment of according to claim 1, is characterized in that it is the ethyl cellulose alcoholic solution that 3% polyvidone alcoholic solution or mass concentration are 3% that described binding agent is selected from mass concentration.
10. a kind of dizzy slow releasing tablet of child for the treatment of according to claim 1, is characterized in that described filler is microcrystalline Cellulose, calcium sulfate, lactose, polyvidone or amylum pregelatinisatum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410191470.0A CN103920134A (en) | 2014-05-08 | 2014-05-08 | Sustained release tablet for treating child vertigo and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410191470.0A CN103920134A (en) | 2014-05-08 | 2014-05-08 | Sustained release tablet for treating child vertigo and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103920134A true CN103920134A (en) | 2014-07-16 |
Family
ID=51138676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410191470.0A Pending CN103920134A (en) | 2014-05-08 | 2014-05-08 | Sustained release tablet for treating child vertigo and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103920134A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106108176A (en) * | 2016-07-08 | 2016-11-16 | 何彩芳 | A kind of Anti-carsickness mask |
| CN107898989A (en) * | 2017-12-11 | 2018-04-13 | 汤阴县瑞星生物有限公司 | A kind of Chinese medicine composition for treating obstructive sleep apnea syndrome and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012741A1 (en) * | 2002-07-29 | 2004-02-12 | Glaxo Group Limited | Sustained release formulations comprising lamotrigine |
| CN103386103A (en) * | 2013-07-09 | 2013-11-13 | 天津中新药业集团股份有限公司第六中药厂 | Xuangui sustain release tablet and preparation method thereof |
-
2014
- 2014-05-08 CN CN201410191470.0A patent/CN103920134A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012741A1 (en) * | 2002-07-29 | 2004-02-12 | Glaxo Group Limited | Sustained release formulations comprising lamotrigine |
| CN103386103A (en) * | 2013-07-09 | 2013-11-13 | 天津中新药业集团股份有限公司第六中药厂 | Xuangui sustain release tablet and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 丁盛贵: "以通补兼施法为主治疗冠心病五十四例疗效分析", 《湖北中医杂志》, no. 4, 31 December 1986 (1986-12-31) * |
| 于作洋: "《刘弼臣学术思想》", 31 July 2013, article "儿童眩晕" * |
| 任达然: "苓桂术甘汤的临床运用", 《江苏中医杂志》, no. 4, 31 December 1984 (1984-12-31), pages 37 - 38 * |
| 国家药典委员会: "《中华人民共和国药典：2010版.一部》", 31 January 2010, article "麦冬 乌药" * |
| 高学敏: "《中药学》", 31 May 2007, article "乌药 甘草 茯苓" * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106108176A (en) * | 2016-07-08 | 2016-11-16 | 何彩芳 | A kind of Anti-carsickness mask |
| CN107898989A (en) * | 2017-12-11 | 2018-04-13 | 汤阴县瑞星生物有限公司 | A kind of Chinese medicine composition for treating obstructive sleep apnea syndrome and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101129906B (en) | Orally taken traditional Chinese medicine composition for treating tuberculosis | |
| CN102342992B (en) | Chinese medicinal composition for treating insomnia and preparation method of preparation thereof | |
| CN102973801A (en) | Traditional Chinese medicine composition for treating chronic pharyngitis or tonsillitis and preparation method thereof | |
| CN103830632A (en) | Chinese traditional medicine preparation for radically treating psoriasis and multiple skin diseases and preparation method and application thereof | |
| CN103169798A (en) | Chinese medicinal composition for treating meniere disease and preparation method thereof | |
| CN101530562A (en) | Pharmaceutical composition for treating female kidney-yin deficiency | |
| CN106728770B (en) | Traditional Chinese medicine composition for tonifying kidney and replenishing vital essence and preparation method thereof | |
| CN103920134A (en) | Sustained release tablet for treating child vertigo and preparation method thereof | |
| CN101537149A (en) | Pharmaceutical composition for curing eczema | |
| CN102370883A (en) | Chinese herbal medicine for treating insufficient heart blood and restless mind | |
| CN100438892C (en) | Chinese traditional medicine for treating nerve deafness and its preparation process | |
| CN103385973B (en) | Miao medicine for curing liver cancer and preparation method thereof | |
| CN104984097A (en) | Chinese herba preparation for treating primary hypertension and application thereof | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN101670080A (en) | Chinese medicinal composition for chronic gastritis and preparation process thereof | |
| CN101229348B (en) | Chinese traditional medicine compounds for treating tumour and preparing method thereof | |
| CN101194945A (en) | Tablet for treating headache and method for preparing the same | |
| CN104367711A (en) | Pharmaceutical composition for treatment of mesenteric lymphadenitis in children | |
| CN103520475B (en) | A kind of pharmaceutical composition being used for the treatment of skin pruritus | |
| CN103386082B (en) | Miao medicine for curing hepatic cirrhosis and preparation method thereof | |
| CN101647935A (en) | Medicinal composition | |
| CN105641295A (en) | Traditional Chinese medicine composition and application thereof to treatment of rheumatic arthritis | |
| CN105288344A (en) | Traditional Chinese medicinal composition for treating liver and gall calculi, and application thereof | |
| CN105343209A (en) | Herba siegesbeckiae rheumatism dispersible tablet and preparation method thereof | |
| CN105079717A (en) | Pharmaceutical preparation for treating depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140716 |
|
| RJ01 | Rejection of invention patent application after publication |